CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 191 enrolled
Drug / intervention
Dabigatran 75 mg +1 moredrug
Likely dose
Dabigatran 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02149303
NCT02149303N/ACompleted
CompareCT.gov

A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate

Boehringer Ingelheim·observational·Posted May 29, 2014·Updated Apr 4, 2016

In Brief

An observational study evaluating Dabigatran 75 mg and Dabigatran 150 mg for Atrial Fibrillation and Hemorrhage. Completed, enrolled 191 participants across 5 sites.

Detailed Summary

This study is being conducted to collect data on the management of major bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Hemorrhage
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 29, 2014
Enrollment StartJun 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.1 years ago

Interventions

Dabigatran 75 mgdrug

PO BID

Dabigatran 150 mgdrug

PO BID